C9021 HCPCS Level II code: Injection, obinutuzumab, 10 mg
CMS terminated C9021: its last date of service was Dec 31, 2014. It stays here for looking up older claims; newer services need a current code.
Official description
C9021Injection, obinutuzumab, 10 mg
Short description: Injection, obinutuzumab
HCPCS · United States
Medicare details
The indicators CMS publishes with C9021 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Other medical items or services; Ambulatory surgical center (facility usage for surgical services)
- BETOS category
- Chemotherapy
- Coverage statute
- 1833(t)
- Added
- Apr 1, 2014
- Terminated after
- Dec 31, 2014
Where C9021 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9021Injection, obinutuzumab, 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9021 still valid?
No. CMS terminated C9021; its last date of service was Dec 31, 2014. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9021?
CMS lists C9021’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9021
All C codesC8936Magnetic resonance angiography without contrast followed by with contrast, upper extremityC8937Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician…C8957Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pumpC9014Injection, cerliponase alfa, 1 mgC9015Injection, c-1 esterase inhibitor (human), haegarda, 10 unitsC9016Injection, triptorelin extended release, 3.75 mgC9022Injection, elosulfase alfa, 1mgC9023Injection, testosterone undecanoate, 1 mgC9024Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabineC9025Injection, ramucirumab, 5 mgC9026Injection, vedolizumab, 1 mgC9027Injection, pembrolizumab, 1 mg